{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:53:35Z","timestamp":1793681615657,"version":"4.5.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and\/or chimeric antigen receptor (CAR) T-cell therapy and those with high-risk features, have poor outcomes. The bispecific antibody, mosunetuzumab, combined with the antibody-drug conjugate (ADC), polatuzumab vedotin (Mosun-Pola), targets CD20 and CD79b via independent cell-killing mechanisms. In this multicenter phase 2 study, patients with MCL who had received \u22652 previous lines of therapy, including a BTK inhibitor, were enrolled. Patients received outpatient fixed-duration mosunetuzumab subcutaneously (17 cycles), with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS), and polatuzumab vedotin (1.8 mg\/kg IV) for 6 cycles. The primary end point was centrally assessed best objective response rate. A total of 42 patients with a median of 3 previous therapies were enrolled; 26% had previous CAR T-cell therapy. A number of patients had MCL with high-risk features (Ki-67 of \u226550%, 67%; blastoid\/pleomorphic morphology, 38%; TP53 aberration, 48%). Objective response occurred in 88.1% of evaluable patients (95% confidence interval [CI], 74.4-96.0) and complete response in 78.6% (95% CI, 63.2-89.7). With a median follow-up of 15.9 months, median progression-free survival was 18.6 months (95% CI, 13.9 to not estimable). Consistent efficacy was observed in high-risk subgroups. CRS occurred in 42.9% of patients and was limited to grade 1\/2 events. Mosun-Pola achieved high complete remission rates while maintaining a manageable safety profile in patients with R\/R MCL exhibiting high-risk features. This is, to our knowledge, the first bispecific-ADC combination therapy study in MCL. This trial was registered at www.clinicaltrials.gov as #NCT03671018.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032422","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:06:32Z","timestamp":1776791192000},"page":"682-692","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Mosunetuzumab plus polatuzumab vedotin for relapsed\/refractory MCL after BTK inhibitor therapy: a phase 2 study"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"first","affiliation":[{"name":"1City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"2Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-1589","authenticated-orcid":false,"given":"Sarit E.","family":"Assouline","sequence":"additional","affiliation":[{"name":"3Jewish General Hospital, McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"4Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"5Levine Cancer Institute\/Advocate Health, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-6491","authenticated-orcid":false,"given":"Thomas A.","family":"Ollila","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-2033","authenticated-orcid":false,"given":"Daniel J.","family":"Hodson","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8844","authenticated-orcid":false,"given":"Dipenkumar","family":"Modi","sequence":"additional","affiliation":[{"name":"8Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Gregorio Mara\u00f1\u00f3n Research Institute, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-151X","authenticated-orcid":false,"given":"Seema G.","family":"Naik","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Penn State University College of Medicine, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia K.","family":"Nakhoda","sequence":"additional","affiliation":[{"name":"11Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Lee Batlevi","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Makadia","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Kwan","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jing","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahib","family":"Ead","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Pham","sequence":"additional","affiliation":[{"name":"13Hoffmann-La Roche Ltd, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"To","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[{"name":"12Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"14The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2026081910162847000_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.18697","article-title":"How I manage mantle cell lymphoma: indolent versus aggressive disease","volume":"201","author":"Wilson","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"2026081910162847000_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"6","key":"2026081910162847000_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026081910162847000_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"2026081910162847000_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/jpm12030376","article-title":"Relapsed\/refractory mantle cell lymphoma: beyond BTK inhibitors","volume":"12","author":"Burkart","year":"2022","journal-title":"J Pers Med"},{"issue":"9","key":"2026081910162847000_bib6","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"36","key":"2026081910162847000_bib7","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-risk mantle cell lymphoma: definition, current challenges, and management","volume":"38","author":"Jain","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026081910162847000_bib8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","article-title":"Blastoid mantle cell lymphoma","volume":"34","author":"Jain","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"2026081910162847000_bib9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.2023022354","article-title":"High-risk MCL: recognition and treatment","volume":"145","author":"Jain","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026081910162847000_bib10","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"287","key":"2026081910162847000_bib11","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026081910162847000_bib12","author":"Lunsumio","year":"2022"},{"key":"2026081910162847000_bib13","author":"Lunsumio Velo","year":"2022"},{"key":"2026081910162847000_bib14","author":"Lunsumio","year":"2022"},{"key":"2026081910162847000_bib15","author":"Polivy","year":"2019"},{"key":"2026081910162847000_bib16","author":"Polivy","year":"2020"},{"issue":"suppl 1","key":"2026081910162847000_bib17","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2024-197902","article-title":"Mosunetuzumab monotherapy demonstrates encouraging activity and a manageable safety profile in patients with heavily pre-treated relapsed or refractory mantle cell lymphoma [abstract]","volume":"144","author":"Budde","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026081910162847000_bib18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2026081910162847000_bib19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026081910162847000_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"2026081910162847000_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"issue":"27","key":"2026081910162847000_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026081910162847000_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026081910162847000_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2026081910162847000_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"2026081910162847000_bib26","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2021-147937","article-title":"Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed\/refractory B-cell non-Hodgkin lymphomas (R\/R B-NHL): initial results from a phase I\/II study [abstract]","volume":"138","author":"Bartlett","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026081910162847000_bib27","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/bjh.17197","article-title":"Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy","volume":"192","author":"Jain","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2026081910162847000_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"14","key":"2026081910162847000_bib29","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2026081910162847000_bib30","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026081910162847000_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","article-title":"Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update","volume":"28","author":"Bellal","year":"2024","journal-title":"Crit Care"},{"issue":"3","key":"2026081910162847000_bib32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026081910162847000_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2026081910162847000_bib34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"36","key":"2026081910162847000_bib35","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1200\/JCO-25-01957","article-title":"Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial","volume":"43","author":"Budde","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026081910162847000_bib36","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026081910162847000_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"36","key":"2026081910162847000_bib38","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1080\/14796694.2024.2393566","article-title":"Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals","volume":"20","author":"Sureda","year":"2024","journal-title":"Future Oncol"},{"issue":"12","key":"2026081910162847000_bib39","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"24","key":"2026081910162847000_bib40","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026081910162847000_bib41","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/682\/2536557\/blood_bld-2025-032422-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/682\/2536557\/blood_bld-2025-032422-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:16:39Z","timestamp":1787148999000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/6\/682\/567888\/Mosunetuzumab-plus-polatuzumab-vedotin-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032422","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,6]]},"published":{"date-parts":[[2026,8,6]]}}}